Riccardo Manetti - Dynavax Technologies Business President
| DVAX Stock | | | USD 11.14 0.28 2.58% |
President
Riccardo Manetti is Business President of Dynavax Technologies
| Phone | 510 848 5100 |
| Web | https://www.dynavax.com |
Dynavax Technologies Management Efficiency
Dynavax Technologies' management efficiency ratios could be used to measure how well Dynavax Technologies manages its routine affairs as well as how well it operates its assets and liabilities.
Dynavax Technologies currently holds 254.42
M in liabilities with Debt to Equity
(D/E) ratio of 0.61, which is about average as compared to similar companies. Dynavax Technologies has a current ratio of 2.71, suggesting that it is
liquid enough and is able to pay its financial obligations when due. Note, when we think about Dynavax Technologies' use of debt, we should always consider it together with its cash and equity.
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California. Dynavax Technologies operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 311 people. Dynavax Technologies (DVAX) is traded on NASDAQ Exchange in USA. It is located in 2100 Powell Street, EmeryVille, CA, United States, 94608 and employs 405 people. Dynavax Technologies is listed under Pharmaceutical Products category by Fama And French industry classification.
Management Performance
Dynavax Technologies Leadership Team
Elected by the shareholders, the Dynavax Technologies' board of directors comprises two types of representatives: Dynavax Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Dynavax. The board's role is to monitor Dynavax Technologies' management team and ensure that shareholders' interests are well served. Dynavax Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Dynavax Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Riccardo Manetti, Business President | |
| Eric Frings, Site VP | |
| Joe Metzinger, VP Officer | |
| Robert Janssen, Chief Medical Officer, Vice President - Clinical Development and Regulatory Affairs | |
| David Novack, Sr. VP of Operations and Quality | |
| Robert MD, Medical Development | |
| Donn Casale, Senior Officer | |
| Nicole Arndt, Sr Relations | |
| Kelly MacDonald, Senior CFO | |
| Paul Cox, VP Communications | |
| Dong Yu, Senior Research | |
| Ryan Spencer, Interim Co-President Co-Principal Executive Officer | |
| John Slebir, Senior Counsel | |
| Jeff Coon, CHRO Administration | |
| Kelly CPA, Principal VP | |
| Justin Burgess, Principal Controller | |
| Andrew Davis, Chief Officer | |
| Michael Ostrach, Principal Financial Officer, Vice President General Counsel, Chief Business Officer | |
| Meg Smith, VP Operations | |
| Todd Lopeman, Senior Operations | |
Dynavax Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Dynavax Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Tools for Dynavax Stock Analysis
When running Dynavax Technologies' price analysis, check to
measure Dynavax Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dynavax Technologies is operating at the current time. Most of Dynavax Technologies' value examination focuses on studying past and present price action to
predict the probability of Dynavax Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dynavax Technologies' price. Additionally, you may evaluate how the addition of Dynavax Technologies to your portfolios can decrease your overall portfolio volatility.